Mammalian Target of Rapamycin Is a Critical Regulator of Cardiac Hypertrophy in Spontaneously Hypertensive Rats

Will Soesanto, Han-yi Lin, Eric Hu, Shane Lefler, Sheldon E. Litwin, Sandra Sena, E. Dale Abel, J. David Symons, Thunder Jalili

Abstract—Evidence exists that protein kinase C and the mammalian target of rapamycin are important regulators of cardiac hypertrophy. We examined the contribution of these signaling kinases to cardiac growth in spontaneously hypertensive rats (SHRs). Systolic blood pressure was increased \( (P<0.001) \) at 10 weeks in SHRs versus Wistar-Kyoto controls \( (162\pm3 \text{ versus } 128\pm1 \text{ mm Hg}) \) and was further elevated \( (P<0.001) \) at 17 weeks in SHRs \( (184\pm7 \text{ mm Hg}) \). Heart:body weight ratio was not different between groups at 10 weeks but was \( 22\% \) greater \( (P<0.01) \) in SHRs versus Wistar-Kyoto controls at 17 weeks. At 10 weeks, activation of Akt and S6 ribosomal protein was greater \( (P<0.01) \) in SHRs but returned to normal by 17 weeks. In contrast, SHRs had protein kinase C activation only at 17 weeks. To determine whether mammalian target of rapamycin regulates the initial development of hypertrophy, rats were treated with rapamycin \( (2 \text{ mg/kg per day IP}) \) or saline vehicle from 13 to 16 weeks of age. Rapamycin inhibited cardiac mammalian target of rapamycin activation only at 17 weeks. These data show that mammalian target of rapamycin is required for the development of cardiac hypertrophy evoked by rising blood pressure in SHRs. \( \text{(Hypertension. 2009; 54:1321-1327.)} \)

Key Words: heart \( \bullet \) blood pressure \( \bullet \) signal transduction \( \bullet \) hypertrophy \( \bullet \) mTOR

Over the last decade, much research has focused on identifying the signaling pathways that regulate cardiac hypertrophy. Among these pathways, protein kinase C (PKC) and the mammalian target of rapamycin (mTOR) have emerged as potentially important regulators of cardiac hypertrophy.\(^1\)

PKC is a family of serine-threonine kinases consisting of 11 isoforms in the heart.\(^2\) Studies using transgenic mice with cardiac specific overexpression of PKC\( \beta II \) or \( \delta \), and mice with overexpression of peptide activators of PKC \( \delta \) and \( \varepsilon \), have reported that these isoforms regulate pathological (PKC\( \beta II \)) and/or physiological cardiac hypertrophy (PKC\( \delta \) and \( \varepsilon \)).\(^3,6\) Similarly, humans with hypertrophy and heart failure exhibit activation of PKC-\( \alpha \) and -\( \beta \).\(^7\)

Signaling through components of the mTOR pathway is an important regulator of normal cardiac growth and pathological hypertrophy. For example, overexpression of phosphoinositide 3-kinase 3-kinase in mice results in Akt activation and increased heart size, whereas overexpression of dominant-negative phosphoinositide 3-kinase leads to decreased Akt activation and reduced heart size.\(^8\) Other studies using cardiac-specific overexpression of Akt report that development of both physiological and pathological hypertrophy is correlated with the degree of Akt activation.\(^9,10\) Human studies examining components of mTOR signaling during hypertrophy or heart failure are scarce, and what data exists is conflicting. For example, it has been reported that implantation of a left ventricular assist device in patients with heart failure resulted in cardiac improvements (reduced left ventricular end-diastolic dimensions and apoptosis), associated with a reduction in phosphorylated (p)-Akt.\(^11\) In contrast, a more recent study stated that hypertensive patients without heart failure had higher p-Akt than patients with heart failure.\(^12\) Therefore, the role of the mTOR signaling pathway during human hypertrophy and heart failure remains unclear.

In the present study, we tested the hypothesis that PKC and mTOR contribute to cardiac hypertrophy that develops in spontaneously hypertensive rats (SHRs). We chose the SHR because these animals model human hypertension and cardiac growth. In this regard, these rats are normotensive at 6 weeks of age but develop hypertension and cardiac hypertrophy at \( \approx 12 \) weeks of age and heart failure by \( \approx 24 \) months.\(^13,14\) Data provided herein show that signaling via mTOR, but not PKC, is increased in SHRs during the development of cardiac hypertrophy (ie, at 10 weeks). Furthermore, when mTOR was
inhibited using rapamycin, cardiac hypertrophy was attenuated independent of changes in blood pressure. These data show clearly that mTOR is required for the initiation and full development of cardiac hypertrophy evoked by rising blood pressure in SHRs.

### Methods

Please see the online Data Supplement at http://hyper.ahajournals.org for a detailed description of the methods and experimental groups.

### Animals

All of the protocols were approved by the University of Utah Institutional Animal Care and Use Committee. Six-week–old male SHR (n = 42) and Wistar Kyoto rats (WKY; n = 24) were purchased from Harlan (Indianapolis, IN) and housed in the University of Utah Comparative Medicine Center under standard conditions (12:12-hour light:dark cycle) and were allowed free access to food and water. Rapamycin was purchased from LC Laboratories.

### Blood Pressure

Blood pressure was measured using a fluid-filled catheter placed into the caudal artery of rats anesthetized with 2% to 5% isoflurane.15,16 After rats regained consciousness, blood pressure was measured over 20 cardiac cycles.

### RNA Extraction and Quantitative RT-PCR

Total RNA was extracted from the left ventricle (LV) using TRizol reagent (Invitrogen) and purified using the RNeasy total RNA isolation kit (Qiagen). RT-PCR was done as detailed by Boudina et al.17

### Tissue Homogenization and Western Blotting

Homogenization of the LV, electrophoresis, and transfer of proteins to polyvinylidene difluoride membranes were done as we have described previously.18,19 Western blots were verified in duplicate if no significant differences were observed or triplicate if significant differences were present.

### Myocardial Function

Cardiac function was determined in a subset of SHRs after 3 weeks of rapamycin (2 mg/kg IP; n = 5) or vehicle (saline; n = 5) treatment using echocardiography.15

### Statistical Analysis

An ANOVA was used to detect differences among groups using SPSS version 11 for Macintosh (SPSS Inc). When a significant P value was obtained (P < 0.05), post hoc procedures were performed using the least significant difference analysis to identify individual group differences. Results are presented as mean ± SE.

### Results

PKC, mTOR, Cardiac Mass, and Blood Pressure in 10-Week– and 17-Week–Old SHRs

At 10 weeks of age, heart:body weight ratio was similar in WKYs versus SHRs (Table 1). In contrast, cardiac hypertrophy was present in 17-week–old SHRs, as evidenced by increased heart:body weight ratio versus WKYs (Table 1). Systolic blood pressure was 26% higher in 10-week–old SHRs compared with WKYs and 33% greater in 17-week–old SHRs versus WKYs (Table 1).

There were no differences detected in total protein expression of PKC-α, PKC-βII, PKC-δ, or PKC-ε in SHRs versus WKYs at either age (Figure 1A; data not shown for PKCδ). Levels of p-PKC-ε were also similar at both ages of SHRs and WKYs (Figure 1A). p-PKC-δ was not detected in the myocardium of SHRs or WKYs. This might be because of a lack of specificity of the primary antibody against rat heart p-PKC-δ rather than an absence of p-PKC-δ. There was no change in p-PKC-α/βII in 10-week–old SHRs versus their age-matched controls. However, 17-week–old SHRs had an ~80% increase in p-PKC-α/βII versus WKYs (Figure 1A). To control for any possible protein loading differences, the p-PKC-α/βII:total PKC-βII ratio was determined and found to be significantly greater in 17-week–old SHRs versus WKYs (Figure 1A). Similar results were obtained with the p-PKC-α/βII:total PKCα ratio (data not shown). After these initial experiments, we also examined PKC status at 14.5 weeks in a subset of SHRs and WKYs but found no change in p-PKC-α/βII at this age (data not shown), p-AktSer473, and the ratio of p-AktSer473:total Akt were ~70% greater in 10-week–old SHRs but unchanged in 17-week–old SHRs compared with age-matched WKYs (Figure 1B).

### Statistical Analysis

An ANOVA was used to detect differences among groups using SPSS version 11 for Macintosh (SPSS Inc). When a significant P value was obtained (P < 0.05), post hoc procedures were performed using the least significant difference analysis to identify individual group differences. Results are presented as mean ± SE.

### mTOR Signaling and Cardiovascular Variables in Rats Treated With Rapamycin

We reasoned that mTOR signaling might regulate the development of hypertrophy, because both Akt and S6 phosphorylation were greater at 10 but not 17 weeks in SHRs versus WKYs. To address this, 13-week–old SHRs were treated with rapamycin or vehicle for 3 weeks, a duration similar to those used in pressure-overload experiments.19 In this experiment we did not use a rapamycin-treated WKY group because cardiac mass has been reported to be unaffected by this drug in control animals.20,21 Thirteen-week–old SHRs were chosen because our preliminary studies indicated that cardiac hypertrophy is minimal at this time, and p-AKT is still elevated, whereas p-PKCα/βII is normal in 14.5-week–old SHRs. inhibition of mTOR signaling by our rapamycin treatment regimen (Rap) was confirmed by ~4-fold reduction in levels of p-S6Ser235/236 and p-E-BP1Thr37/46 in SHR-Rap versus SHR-Veh and WKY-Veh (vehicle; Figure 2). p-AktSer473 was reduced ~80% in SHR-Rap (Figure 2).
Taken together, signaling through mTOR in the heart was markedly reduced in rapamycin-treated SHRs.

Heart weights were lower in SHR-Rap rats than SHR-Veh rats but still greater than WKY-Veh rats (Table 2). As expected, blood pressure was greater in SHRs versus WKYs, but surprisingly it was even higher in SHR-Rap rats versus SHR-Veh rats (Table 2). Rapamycin-treated SHRs had lower body weight than WKY-Veh or SHR-Veh rats (Table 2). Heart mass was, therefore, normalized to tibia length for the rapamycin studies. In spite of increased blood pressure in the SHR-Rap rats, cardiac hypertrophy was attenuated (heart: tibia length) versus SHR-Veh rats but was still greater than WKY-Veh rats (Table 2). Rapamycin-treated SHRs had lower body weight than WKY-Veh or SHR-Veh rats (Table 2). Heart mass was, therefore, normalized to tibia length for the rapamycin studies.

It is possible that the combination of exaggerated hypertension and attenuated hypertrophy in SHR-Rap versus SHR-Veh rats might lead to increased wall stress and cardiac dysfunction. However, there was no echocardiographic evidence for LV dysfunction, because both ejection fraction and fractional shortening were similar in SHR-Veh and SHR-Rap rats (Figure 3D). Interventricular septal dimension, left ventricular diastolic dimension, and left ventricular posterior wall dimension were also similar in SHR-Rap versus SHR-Veh rats (data not shown).

**Discussion**

The contribution of mTOR signaling to cardiac hypertrophy that develops in response to a gradual increase in afterload, as occurs in the SHR, is unknown. In the present study, we observed activation of mTOR signaling in hearts of young SHRs during the developmental stage of cardiac hypertrophy. Pharmacologically inhibiting this pathway attenuated the extent of cardiac hypertrophy that ultimately occurs in this model. These are the first data indicating that mTOR signaling contributes importantly to cardiac hypertrophy in a clinically relevant model of hypertension.

Studies using pressure-overloaded mice and guinea pigs reported that P70 S6 ribosomal kinase phosphorylation is clearly correlated with cardiac hypertrophy and that
cardiac-specific Akt overexpression increases activation of mTOR and results in cardiac hypertrophy. The in vivo importance of mTOR has also been demonstrated in pressure-overloaded rodents where rapamycin treatment results in inhibition of mTOR, as determined by downstream effectors, such as p70 S6 ribosomal kinase, and attenuates cardiac function in mice, whereas adenoviral transfection of PKC-\(\beta\)II diminished ventricular function. Similarly, inhibition of PKC-\(\beta\)II, -\(\gamma\), and -\(\delta\) has been found to result in cardiac hypertrophy in mice. Interestingly, mice with deletion of PKC-\(\beta\) still develop cardiac hypertrophy in response to pressure overload or phenylephrine, and overexpression of PKC-\(\alpha\) does not cause cardiac hypertrophy but results in diminished ventricular function. Similarly, inhibition of conventional PKC isoforms (\(\alpha\), \(\beta\), and \(\gamma\)) increases cardiac function in mice, whereas adenoviral transfection of PKC-\(\alpha\) reduces cardiac contractility in the normally hypercontractile PKC-\(\alpha\) knockout mouse. In contrast to our original hypothesis, we did not find activation of any PKC isoform in 10-week-old SHRs during the developmental phase of cardiac hypertrophy evoked by aortic constriction. The studies using pressure-overloaded models are important; however, it should be noted that aortic constriction creates local hypertension and does so in an abrupt manner. This process differs from the SHR that has gradually increasing systemic hypertension that eventually results in cardiac hypertrophy. The SHR may be considered to be more clinically relevant to the human experience, where uncontrolled hypertension leads to cardiac hypertrophy. In the present study, rapamycin-treated SHRs demonstrated a clear and robust reduction in the phosphorylation of S6 and 4E-BP1, both downstream targets of mTOR, and, thus, provided mechanistic evidence of the role of mTOR in the development of cardiac hypertrophy.

**Table 2. Characteristics of WKYs and SHRs Treated With Vehicle or 2 mg/kg of Rapamycin**

<table>
<thead>
<tr>
<th>Variable</th>
<th>WKY-Veh</th>
<th>SHR-Veh</th>
<th>SHR-Rap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, wk</td>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>No.</td>
<td>7</td>
<td>11</td>
<td>14</td>
</tr>
<tr>
<td>Heart weight, mg</td>
<td>827±26</td>
<td>1244±21*</td>
<td>1080±18†</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>252±4</td>
<td>322±3*</td>
<td>269±3†</td>
</tr>
<tr>
<td>Tibia length, mm</td>
<td>36.1±0.2</td>
<td>38.3±0.2*</td>
<td>38.0±0.2*</td>
</tr>
<tr>
<td>No.</td>
<td>7</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>376±11</td>
<td>390±10</td>
<td>405±13</td>
</tr>
<tr>
<td>Caudal blood pressure, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>139±6</td>
<td>189±7*</td>
<td>213±6†</td>
</tr>
<tr>
<td>Diastolic</td>
<td>118±6</td>
<td>156±7*</td>
<td>171±6*</td>
</tr>
<tr>
<td>Mean arterial pressure</td>
<td>125±6</td>
<td>167±7*</td>
<td>184±5†</td>
</tr>
</tbody>
</table>

Data are mean±SE. WKY indicates normotensive control rats treated with saline vehicle (Veh IP from 13 to 16 weeks of age). SHR-Rap rats were treated with 2 mg/kg of rapamycin from 13 to 16 weeks of age.

\(P<0.05\) vs WKYs.

\(†P<0.05\) vs SHRs.
cardiac hypertrophy. However, 17-week-old SHRs had an increase in p-PKC-α/βII. Although no other studies have examined PKC during the developmental phase of hypertrophy in the SHR, others have found PKC-α, -δ, and -ε activation in 6-month-old spontaneously hypertensive heart failure rats and PKC-β activation in 16-week-old Dahl salt-sensitive rats. Given the lack of PKC activation in hypertensive 10-week-old SHRs without hypertrophy, one may speculate that the PKC alterations in spontaneously hypertensive heart failure rats and Dahl salt-sensitive rats with established hypertrophy may be related to the regulation of cardiac function rather than growth.

In the present study, we found that treating SHRs with rapamycin for 3 weeks resulted in even greater blood pressure compared with vehicle-treated SHRs. This is consistent with previous studies reporting detrimental changes in kidney function, along with tubular atrophy and vascular pathology, after treating with 0.8 mg/g of rapamycin for 2 weeks. Although hypertension has not been a reported adverse effect of rapamycin, it should be noted that clinical use in human clinical trials using long-term rapamycin treatment is attributable solely to the inhibition of mTOR, without fundamentally altering the pathological nature of the residual hypertrophy that develops in SHR-Rap rats or the increase in wall stress. Given the disproportional degree of hypertrophy versus hypertension in rapamycin-treated SHRs, we used echocardiography to evaluate ejection fraction and fractional shortening as measures of cardiac function. We have reported previously that 16-week-old SHRs with cardiac hypertrophy have normal cardiac function compared with age-matched WKYs. In the present study, our data indicated that both ejection fraction and fractional shortening were also similar in vehicle and rapamycin-treated SHRs. We conclude that short-term rapamycin treatment does not adversely affect cardiac function; however, the effect of an extended (≥3 weeks) period of rapamycin treatment on cardiac function remains unknown. A limitation, however, of the present study is the lack of histological analysis of hearts from rapamycin-treated and untreated SHRs. Histological analyses from previous studies indicate that myocyte size is increased in
14-week-old SHRs, whereas cardiac fibrosis develops between 12 and 20 months of age. However, in the present study, it is unknown to what degree rapamycin treatment may have altered cardiac structure with regard to myocyte size in 16-week-old SHRs.

**Perspectives**

Recent studies have reported that sirolimus (rapamycin) treatment can reduce LV hypertrophy in humans that is an adverse effect of kidney transplant and heart transplant. Not surprisingly, these reports have led to suggestions that rapamycin might have therapeutic potential for treating LV hypertrophy in cardiac transplant patients, as well as those with other etiologies, such as hypertension and myocardial infarction. However, our data indicate several factors that should be seriously considered in this regard. For example, transplant patients examined in previous studies did not have hypertension or were under pharmacological blood pressure control, whereas SHRs used in our study were severely hypertensive. This point is noteworthy, because our data indicate that rapamycin in the face of untreated hypertension may worsen the condition. Second, although we achieved more substantial reductions in cardiac hypertrophy in our study (≈50% reduction in developed hypertrophy) compared with those reported in the kidney or heart transplant patients (10% and ≈5% reduction in LV mass index, respectively), our rapamycin doses were much higher in SHRs versus patients (2 mg/kg IP per day in SHRs versus human total dose of 1 mg PO per day). Although our data suggest that a larger reduction of hypertrophy may be possible in clinical situations, safety and efficacy studies would be required to determine a dose of rapamycin that would strike a balance between optimal reductions in hypertrophy and reduced mortality without severe adverse effects. Finally, we have demonstrated in the SHR model that rapamycin markedly inhibits S6 and 4E-BP1, however, it is unclear whether this near total inhibition is actually required to attenuate cardiac hypertrophy. As such, the possibility exists that lower doses of rapamycin might be similarly efficacious in this regard. In light of this, we believe that further research is warranted to elucidate the degree of mTOR inhibition that is associated with LVH regression before any assumptions can be made as to the potential therapeutic use of rapamycin in patients with hypertrophy because of other causes, such as hypertension myocardial infarction.

**Acknowledgments**

T.J. and J.D.S. thank the Undergraduate Research Opportunities Program at the University of Utah for supporting E.H.

**Sources of Funding**

T.J. was supported by grants from the National Institutes of Health (1R15HL085226) and the University of Utah Technology Commercialization Office. J.D.S. was supported by an American Heart Association Grant-in-Aid (0655222Y), the National Institutes of Health (1R15HL091493-01), and an American Diabetes Association Research Grant (7-08-RA-164).

**Disclosures**

None.

**References**


Mammalian Target of Rapamycin Is a Critical Regulator of Cardiac Hypertrophy in Spontaneously Hypertensive Rats
Will Soesanto, Han-yi Lin, Eric Hu, Shane Lefler, Sheldon E. Litwin, Sandra Sena, E. Dale Abel, J. David Symons and Thunder Jalili

Hypertension. published online November 2, 2009;
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/early/2009/11/02/HYPERTENSIONAHA.109.138818.citation

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2009/11/02/HYPERTENSIONAHA.109.138818.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/
mTOR is a critical regulator of cardiac hypertrophy in Spontaneously Hypertensive Rats.

Will Soesanto¹, Han-yi Lin¹, Eric Hu¹, Shane Lefler¹, Sheldon E. Litwin², Sandra Sena³, E. Dale Abel³, J. David Symons¹, Thunder Jalili¹

College of Health¹, Division of Cardiology², Human Molecular Biology and Genetics³, University of Utah, Salt Lake City, UT 84112
METHODS

Animals

In the first series of experiments SHR were evaluated at time points when hypertension and cardiac growth were developing (10 weeks old, n=6) or established (17 weeks old, n=6), and results were compared to an identical number of age-matched WKY rats. Because we observed that mTOR signaling was increased in 10-week old rats, a second series of experiments was performed to test the hypothesis that mTOR is required for development of cardiac hypertrophy in these hypertensive animals. In this experiment thirteen-week old SHR were treated daily with rapamycin, an inhibitor of mTOR, (2 mg/kg i.p.; SHR-Rap, n=14) or saline (SHR-Veh, n=11) for 3 weeks, while age-matched WKY rats treated with saline served as controls (WKY-Veh, n=7). In these experiments we did not use a WKY rapamycin treated group because previous studies have shown that rapamycin does not affect cardiac mass in rodents that do not have pressure overload. To determine whether rapamycin compromised cardiac function in treated SHR cardiac function was evaluated in a subset of 16-week old SHR-Rap and SHR-Veh rats (n=5 per group).

Blood pressure and heart rate

Rats regained consciousness and were allowed to recover for 60-min. Arterial blood pressure and heart rate were measured over ~20 cardiac cycles (Biopac Systems Inc., Santa Barbara, CA). Next, rats were anesthetized again (5% isoflurane), the heart excised and placed immediately in iced physiological saline solution and trimmed of adherent tissue. After hearts were weighed, they were snap frozen in liquid nitrogen, and stored at -80°C. The left ventricle (LV) was used in subsequent experiments to examine signal transduction pathways.

RNA extraction and quantitative RT-PCR

After atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were expressed relative to cyclophilin (CPHN), values were normalized to the mean WKY value. Rat primer sequences were: CPHN-for 5’-AGCCTGGAAGAGATGATGG-3’, CPHN-rev 5’-TCTTTGCTGTCTTGGCCATT-3’, ANP-for 5’-GGGGGTAGGAGGGTGTTTAT-3’, ANP-rev 5’-CTCCAGCATGGTATCCCA-3’, BNP-for 5’-GACGGGCTGAGTTTTTA-3’, BNP-rev 5’-ACTGTGGCAAGTTTGTGCTG-3’.

Tissue homogenization and Western blotting

All homogenization procedures were performed at 4°C. The LV was homogenized with a tissue grinder in 1 ml of ice-cold RIPA buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1mM sodium orthovanadate, 1mM NaF, and 10 μl/mL Sigma protease inhibitor cocktail (Sigma, St. Louis, MO, cat. #P-8340)]. After homogenization, samples were sonicated on ice and centrifuged at 11,000 × g for 10 min at 4°C. Protein concentration was determined using a BioRad Protein assay (BioRad, Hercules,
CA) with bovine serum albumin (BSA) as a standard. Cardiac homogenates were stored at –80°C for subsequent Western blotting.

Antibodies directed against PKCα, βII, ε, δ, and p-PKCεSer729 and GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies directed against p-AktThr308, p-AktSer473, total Akt, p-PKCα/βIIThr638/641 and p-PKCδThr505, S6 ribosomal protein (S6), p-S6Ser235/236, eukaryotic translation initiation factor-4E binding protein-1 (4E-BP1), p-4E-BP1Thr37/46 were purchased from Cell Signal Technology (Beverly, MA). All primary antibodies were incubated overnight at 4°C in a 1:1000 dilution in 5% BSA in Tris buffer with 0.05% Tween-20 (phospho specific antibodies) or 5% nonfat milk (non-phospho specific antibodies). Secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit, Cell Signal Technology, Beverly, MA) was incubated for 1 h at 1:10,000 dilution. Signals were visualized by enhanced chemiluminescence (Cell Signal Technology, Beverly, MA). After exposure, membranes were stripped and probed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control (Chemicon, Temecula, CA). Relative band densities of immunoblots were measured using a Kodak GL1500 gel imaging system.

**Myocardial Function**

Rats were anesthetized with 2-5% isoflurane and two dimensional-guided M-mode images of the left ventricle were obtained using a General Electric Vivid 5 echocardiographic machine equipped with a 10-MHz transducer. Digital images were analyzed offline by a blinded observer.

**References**